Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:5339070
0-(bis(2,3-dimethyl-l-aziridinyl)phosphinyl)-N-hydroxyurethane AB182, in combination with irradiation, was investigated in the P388 lymphocytic leukemia system. Combined modality effectiveness appeared to be associated with radiation dose and tumor stage. Cytotoxicity studies indicated that the drug alone was cytotoxic and potentiated cell killing when it was used in combination with radiation.
Research Organization:
Arthur D. Little, Inc., Cambridge, MA
OSTI ID:
5339070
Conference Information:
Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 5:9
Country of Publication:
United States
Language:
English

Similar Records

Synthesis of potential dual-acting radiation sensitizer antineoplastic agents: 2,2-dimethylphosphoraziridines containing 2-nitroimidazoles or other electron-affinic moieties
Journal Article · Sun Mar 31 23:00:00 EST 1991 · Journal of Medicinal Chemistry; (USA) · OSTI ID:5639476

Radiation potentiating effect of ethyl bis(2,2-dimethyl-l-aziridinyl) phosphinate (AB-163)
Conference · Sat Sep 01 00:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5275165

Interaction of. gamma. -irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'-(acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo
Conference · Sat Sep 01 00:00:00 EDT 1979 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5275211